(2R,6R)-Hydroxynorketamine Do Not Block NMDA Receptor Function

Total Page:16

File Type:pdf, Size:1020Kb

(2R,6R)-Hydroxynorketamine Do Not Block NMDA Receptor Function Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function Eric W. Lumsdena,1, Timothy A. Troppolib,1, Scott J. Myersc, Panos Zanosd, Yasco Aracavaa, Jan Kehre,f, Jacqueline Lovettg, Sukhan Kimc, Fu-Hua Wange,f, Staffan Schmidte,f, Carleigh E. Jenned, Peixiong Yuanh, Patrick J. Morrisi, Craig J. Thomasi, Carlos A. Zarate Jr.h, Ruin Moaddelg, Stephen F. Traynelisc,2, Edna F. R. Pereiraa,j,2, Scott M. Thompsonb,d,2, Edson X. Albuquerquea,j,k,2, and Todd D. Gouldd,j,l,m,2,3 aDepartment of Epidemiology and Public Health, Division of Translational Toxicology, University of Maryland School of Medicine, Baltimore, MD 21201; bDepartment of Physiology, University of Maryland School of Medicine, Baltimore, MD 21201; cDepartment of Pharmacology, Emory University, Atlanta, GA 30329; dDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201; eDepartment of Physiology and Pharmacology, Karolinska Institute, SE-171 77 Stockholm, Sweden; fPronexus Analytical AB, SE-167 33 Bromma, Sweden; gBiomedical Research Center, National Institute on Aging, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224; hSection on the Neurobiology and Treatment of Mood Disorders, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892; iDivision of Preclinical Innovation, National Center for Advancing Translational Sciences, Intramural Research Program, National Institutes of Health, Bethesda, MD 20892; jDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, MD 21201; kDepartment of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201; lDepartment of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD 21201; and mVeterans Affairs Maryland Health Care System, Baltimore, MD 21201 Edited by Solomon H. Snyder, Johns Hopkins University School of Medicine, Baltimore, MD, and approved January 24, 2019 (received for review September 19, 2018) Preclinical studies indicate that (2R,6R)-hydroxynorketamine (HNK) Significance is a putative fast-acting antidepressant candidate. Although inhibi- tion of NMDA-type glutamate receptors (NMDARs) is one mecha- Standard antidepressant treatments require weeks to show effec- ’ nism proposed to underlie ketamine s antidepressant and adverse tiveness. A single subanesthetic dose of ketamine rapidly attenu- R R effects, the potency of (2 ,6 )-HNK to inhibit NMDARs has not been ates many clinical signs and symptoms of depression; however, established. We used a multidisciplinary approach to determine the ketamine treatment also has many adverse effects, including dis- R R effects of (2 ,6 )-HNK on NMDAR function. Antidepressant-relevant sociation and potential for abuse, which are mediated by NMDA R R behavioral responses and (2 ,6 )-HNK levels in the extracellular glutamate receptor (NMDAR) inhibition. Previous work has revealed compartment of the hippocampus were measured following sys- that the ketamine metabolite (2R,6R)-hydroxynorketamine (HNK) R R temic (2 ,6 )-HNK administration in mice. The effects of ketamine, induces antidepressant-like responses in rodents while minimizing R R S S (2 ,6 )-HNK, and, in some cases, the (2 ,6 )-HNK stereoisomer were the adverse effects observed with ketamine. The results of this i ii evaluated on the following: ( ) NMDA-induced lethality in mice, ( ) study, using a multitude of experimental approaches, confirm that NMDAR-mediated field excitatory postsynaptic potentials (fEPSPs) antidepressant-relevant concentrations of (2R,6R)-HNK are not suf- iii in the CA1 field of mouse hippocampal slices, ( )NMDAR- ficient to block NMDARs. This provides a basis for work directed at mediated miniature excitatory postsynaptic currents (mEPSCs) and alternative molecular targets and toward novel drugs that exert NMDA-evoked currents in CA1 pyramidal neurons of rat hippocam- rapid antidepressant effects independent of NMDAR inhibition and iv Xenopus pal slices, and ( ) recombinant NMDARs expressed in oo- NMDAR-mediated adverse effects. cytes. While a single i.p. injection of 10 mg/kg (2R,6R)-HNK exerted antidepressant-related behavioral and cellular responses in mice, Author contributions: E.W.L., T.A.T., S.J.M., P.Z., Y.A., J.K., S.F.T., E.F.R.P., S.M.T., E.X.A., the ED50 of (2R,6R)-HNK to prevent NMDA-induced lethality was and T.D.G. designed research; E.W.L., T.A.T., S.J.M., P.Z., Y.A., J.K., J.L., S.K., F.-H.W., S.S., found to be 228 mg/kg, compared with 6.4 mg/kg for ketamine. C.E.J., P.Y., P.J.M., C.J.T., C.A.Z., and R.M. performed research; E.W.L., T.A.T., S.J.M., P.Z., The 10 mg/kg (2R,6R)-HNK dose generated maximal hippocampal Y.A., J.K., C.E.J., and S.F.T. analyzed data; and E.W.L., T.A.T., P.Z., E.F.R.P., S.M.T., E.X.A., and T.D.G. wrote the paper. extracellular concentrations of ∼8 μM, which were well below con- Conflict of interest statement: T.D.G. has received research funding from Janssen, Roche, and centrations required to inhibit synaptic and extrasynaptic NMDARs Allergan Pharmaceuticals, and served as a consultant for FSV7 LLC during the preceding in vitro. (2S,6S)-HNK was more potent than (2R,6R)-HNK, but less 3 years. The authors declare competing financial interests: T.D.G., P.Z., R.M., P.J.M., C.J.T., potent than ketamine at inhibiting NMDARs. These data demon- and C.A.Z. are listed as co-inventors on a patent application for the use of (2R,6R)-hydroxy- strate the stereoselectivity of NMDAR inhibition by (2R,6R;2S,6S)- norketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhe- donia, suicidal ideation, and post-traumatic stress disorders. C.A.Z. and R.M. are listed as co- HNK and support the conclusion that direct NMDAR inhibition does inventors on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, not contribute to antidepressant-relevant effects of (2R,6R)-HNK. and other stereoisomeric dehydro- and hydroxylated metabolites of ketamine metabolites in the treatment of depression and neuropathic pain. R.M., P.J.M., C.J.T., and C.A.Z. have as- depression | ketamine | hydroxynorketamine | antidepressant | signed patent rights to the US Government but will share a percentage of any royalties that may be received by the Government. P.Z. and T.D.G. have assigned their patent rights to the NMDA receptor University of Maryland, Baltimore, but will share a percentage of any royalties that may be received by the University of Maryland, Baltimore. S.F.T. received research support from ajor depressive disorder (MDD) occurs in about 16% of Janssen, is a consultant for Janssen, is a member of the Scientific Advisory Board for Sage Therapeutics, is a co-founder of NeurOp, Inc., and co-inventor on Emory-owned IP. S.J.M. owns Mthe population over the course of a lifetime (1). It is esti- stock in NeurOp, Inc., which is developing NMDAR inhibitors for use in treating neurological mated that MDD affected nearly 7% of all US adults in 2016, disease and disorders. All other authors declare no competing interests. and that one-half of those individuals were prescribed typical This article is a PNAS Direct Submission. antidepressant medications as part of their treatment regimen Published under the PNAS license. (2). Although such typical antidepressants, including selective 1E.W.L. and T.A.T. contributed equally to this work. serotonin and norepinephrine reuptake inhibitors, tricyclic an- 2S.F.T., E.F.R.P., S.M.T., E.X.A., and T.D.G. contributed equally to this work. tidepressants, and monoamine oxidase inhibitors, can sometimes 3To whom correspondence should be addressed. Email: [email protected]. mitigate clinical symptoms of MDD, the onset of action of these This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. drugs is very slow, requiring daily administration over weeks or 1073/pnas.1816071116/-/DCSupplemental. months for clinical improvement (3). In addition, ∼30% of pa- Published online February 22, 2019. 5160–5169 | PNAS | March 12, 2019 | vol. 116 | no. 11 www.pnas.org/cgi/doi/10.1073/pnas.1816071116 Downloaded by guest on October 6, 2021 tients suffering from MDD fail to respond after attempting (14). Nevertheless, reports that at high concentrations (2R,6R)-HNK multiple treatments (3). The use of (R,S)-ketamine (ketamine) inhibits NMDAR function led to the suggestion that NMDAR in- for the treatment of MDD has generated much excitement be- hibition accounts for (2R,6R)-HNK’s antidepressant-relevant effects cause it reduces, and in some patients eliminates, many core (31, 32). symptoms of depression, including depressed mood, anhedonia, The present study systematically assessed the effects of (2R,6R)- and suicidal ideation, within hours following i.v. administration of HNK on NMDAR function. Tests exploring behavioral despair and ’ a single subanesthetic dose. Furthermore, ketamine is effective in hyponeophagia in mice were employed to confirm the metabolite s – antidepressant-relevant effects. Analytical assays were used to quantify patients who are refractory to typical antidepressants (4 9). R R Although ketamine is a promising alternative to standard clinically plasma, whole-brain, and extracellular hippocampal levels of (2 ,6 )- used antidepressants, it induces adverse effects at antidepressant doses, HNK following systemic treatment of mice with a dose that produces particularly dissociation (10). Furthermore, ketamine, a derivative of the antidepressant-relevant effects. A series of functional tests including in illicit drug phencyclidine, is widely abused (11). Ketamine is rapidly and vivo NMDA-induced lethality and ex vivo electrophysiological mea- stereoselectively metabolized in the liver to a number of metabolites, surements of NMDAR activity in hippocampal neurons and in oocytes including the norketamines, hydroxyketamines, dehydronorketamines, expressing distinct NMDAR subtypes (GluN1/GluN2A, GluN2B, and the hydroxynorketamines (HNKs) (12).
Recommended publications
  • Ketamine As a Rapid Antidepressant
    BJPsych Advances (2016), vol. 22, 222–233 doi: 10.1192/apt.bp.114.014274 ARTICLE Ketamine as a rapid anti depressant: the debate and implications Roger C. M. Ho & Melvyn W. Zhang Roger Ho is an Associate Professor response rates to SSRIs and NaSSAs are around SUMMARY and consultant psychiatrist in 62% and 67% respectively (Papakostas 2008). the Department of Psychological Ketamine, a synthetic derivative of phencyclidine, Environmental factors such as relationship Medicine, Yong Loo Lin School of is a commonly misused party drug that is Medicine, National University of problems, financial difficulties and comorbid restricted in high-income countries because of Singapore. He has a special interest substance misuse often lead to poor treatment its addictive potential. Ketamine is also used as in psychoneuroimmunology and response, and antidepressants combined with the interface between medicine an anaesthetic in human and veterinary medicine. and psychiatry. Melvyn Zhang In the 1990s, research using ketamine to study the CBT have shown promising results in prevention is a senior resident with the pathophysiology of schizophrenia was terminated of mood disorders (Brenner 2010). Although 70– National Addiction Management owing to ethical concerns. Recently, controversy 90% of patients with depression achieve remission, Service, Institute of Mental Health, surrounding the drug has returned, as researchers around 10–30% are refractory to initial treatment Singapore. Correspondence Dr Roger C. M. have demonstrated that intravenous ketamine but respond to switching or combination of Ho, National University of Singapore, infusion has a rapid antidepressant effect and antidepressants, electroconvulsive therapy (ECT) Department of Psychological have therefore proposed ketamine as a novel or psychotherapy.
    [Show full text]
  • Case Discussions in Palliative Medicine Levorphanol For
    JOURNAL OF PALLIATIVE MEDICINE Volume 21, Number 3, 2018 Case Discussions in Palliative Medicine ª Mary Ann Liebert, Inc. DOI: 10.1089/jpm.2017.0475 Feature Editor: Craig D. Blinderman Levorphanol for Treatment of Intractable Neuropathic Pain in Cancer Patients Akhila Reddy, MD,1,* Amy Ng, MD,1,* Tarun Mallipeddi,2 and Eduardo Bruera, MD1 Abstract Neuropathic pain in cancer patients is often difficult to treat, requiring a combination of several different pharmacological therapies. We describe two patients with complex neuropathic pain syndromes in the form of phantom limb pain and Brown-Sequard syndrome who did not respond to conventional treatments but re- sponded dramatically to the addition of levorphanol. Levorphanol is a synthetic strong opioid that is a potent N- methyl-d-aspartate receptor antagonist, mu, kappa, and delta opioid receptor agonist, and reuptake inhibitor of serotonin and norepinephrine. It bypasses hepatic first-pass metabolism and thereby not subjected to numerous drug interactions. Levorphanol’s unique profile makes it a potentially attractive opioid in cancer pain man- agement. Keywords: Brown-Sequard syndrome; cancer; cancer pain; levorphanol; neuropathic pain; phantom limb pain Introduction changes, structural reorganization of spinal cord and primary somatosensory cortex, and increased sensitization of spinal ne-third of cancer patients who experience pain cord may be the neurological basis for PLP.8,9 Because the Oalso experience neuropathic pain1 and about half the pathophysiology of PLP is not clearly understood, the treat- patients with cancer who suffer from neuropathic pain also ment options are mainly based on clinical experience.9 There have nociceptive pain.2 Most neuropathic pain exists as are case series showing that tramadol and methadone may be mixed pain in combination with nociceptive pain.
    [Show full text]
  • Hallucinogens and Dissociative Drugs
    Long-Term Effects of Hallucinogens See page 5. from the director: Research Report Series Hallucinogens and dissociative drugs — which have street names like acid, angel dust, and vitamin K — distort the way a user perceives time, motion, colors, sounds, and self. These drugs can disrupt a person’s ability to think and communicate rationally, or even to recognize reality, sometimes resulting in bizarre or dangerous behavior. Hallucinogens such as LSD, psilocybin, peyote, DMT, and ayahuasca cause HALLUCINOGENS AND emotions to swing wildly and real-world sensations to appear unreal, sometimes frightening. Dissociative drugs like PCP, DISSOCIATIVE DRUGS ketamine, dextromethorphan, and Salvia divinorum may make a user feel out of Including LSD, Psilocybin, Peyote, DMT, Ayahuasca, control and disconnected from their body PCP, Ketamine, Dextromethorphan, and Salvia and environment. In addition to their short-term effects What Are on perception and mood, hallucinogenic Hallucinogens and drugs are associated with psychotic- like episodes that can occur long after Dissociative Drugs? a person has taken the drug, and dissociative drugs can cause respiratory allucinogens are a class of drugs that cause hallucinations—profound distortions depression, heart rate abnormalities, and in a person’s perceptions of reality. Hallucinogens can be found in some plants and a withdrawal syndrome. The good news is mushrooms (or their extracts) or can be man-made, and they are commonly divided that use of hallucinogenic and dissociative Hinto two broad categories: classic hallucinogens (such as LSD) and dissociative drugs (such drugs among U.S. high school students, as PCP). When under the influence of either type of drug, people often report rapid, intense in general, has remained relatively low in emotional swings and seeing images, hearing sounds, and feeling sensations that seem real recent years.
    [Show full text]
  • Hallucinogens
    Hallucinogens What Are Hallucinogens? Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings as well as their thoughts and feelings. They are commonly split into two categories: classic hallucinogens (such as LSD) and dissociative drugs (such as PCP). Both types of hallucinogens can cause hallucinations, or sensations and images that seem real though they are not. Additionally, dissociative drugs can cause users to feel out of control or disconnected from their body and environment. Some hallucinogens are extracted from plants or mushrooms, and others are synthetic (human-made). Historically, people have used hallucinogens for religious or healing rituals. More recently, people report using these drugs for social or recreational purposes. Hallucinogens are a Types of Hallucinogens diverse group of drugs Classic Hallucinogens that alter perception, LSD (D-lysergic acid diethylamide) is one of the most powerful mind- thoughts, and feelings. altering chemicals. It is a clear or white odorless material made from lysergic acid, which is found in a fungus that grows on rye and other Hallucinogens are split grains. into two categories: Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) comes from certain classic hallucinogens and types of mushrooms found in tropical and subtropical regions of South dissociative drugs. America, Mexico, and the United States. Peyote (mescaline) is a small, spineless cactus with mescaline as its main People use hallucinogens ingredient. Peyote can also be synthetic. in a wide variety of ways DMT (N,N-dimethyltryptamine) is a powerful chemical found naturally in some Amazonian plants. People can also make DMT in a lab.
    [Show full text]
  • Assessment of Combined Toxicity of Heavy Metals from Industrial Wastewaters on Photobacterium Phosphoreum T3S
    Appl Water Sci DOI 10.1007/s13201-016-0385-4 ORIGINAL ARTICLE Assessment of combined toxicity of heavy metals from industrial wastewaters on Photobacterium phosphoreum T3S 1,2 1 2 1 2 BibiSaima Zeb • Zheng Ping • Qaisar Mahmood • Qiu Lin • Arshid Pervez • 2 2 2 Muhammad Irshad • Muhammad Bilal • Zulfiqar Ahmad Bhatti • Shahida Shaheen2 Received: 19 May 2015 / Accepted: 19 January 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com Abstract This research work is focusing on the toxicities Introduction of heavy metals of industrial origin to anaerobic digestion of the industrial wastewater. Photobacterium phospho- The presence of heavy metals in excess amounts inter- reum T3S was used as an indicator organism. The acute feres with the beneficial uses of water because of the toxicities of heavy metals on P. phosphoreum T3S were toxicity of heavy metals and the biomagnification effect assessed during 15-min half inhibitory concentration brought on by its accumulation on ecology (Chang et al. (IC50) as indicator at pH 5.5–6. Toxicity assays involved 2006; Altas 2009). During recent times, heavy metals the assessment of multicomponent mixtures using TU and were focus of attention owing to their hazardous nature MTI approaches. The results of individual toxicity indi- and subsequent toxicity studies. Various workers have cated that the toxicity of Cd, Cu and Pb on P. phospho- assessed the combined toxicity of heavy metals (Su reum increased with increasing concentrations and there et al. 2012;Quetal.2013; Mochida et al. 2006). It has was a linear correlation. The 15-min IC50 values of Cd, Cu been argued that the effects caused by combinations of and Pb were 0.537, 1.905 and 1.231 mg/L, respectively, various heavy metals may be more threatening and and their toxic order was Cd [ Pb [ Cu.
    [Show full text]
  • Hallucinogens
    Hallucinogens What are hallucinogens? Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings as well as their own thoughts and feelings. They are commonly split into two categories: classic hallucinogens (such as LSD) and dissociative drugs (such as PCP). Both types of hallucinogens can cause hallucinations, or sensations and images that seem real though they are not. Additionally, dissociative drugs can cause users to feel out of control or disconnected from their body and environment. Some hallucinogens are extracted from plants or mushrooms, and some are synthetic (human- made). Historically, people have used hallucinogens for religious or healing rituals. More recently, people report using these drugs for social or recreational purposes, including to have fun, deal with stress, have spiritual experiences, or just to feel different. Common classic hallucinogens include the following: • LSD (D-lysergic acid diethylamide) is one of the most powerful mind-altering chemicals. It is a clear or white odorless material made from lysergic acid, which is found in a fungus that grows on rye and other grains. LSD has many other street names, including acid, blotter acid, dots, and mellow yellow. • Psilocybin (4-phosphoryloxy-N,N- dimethyltryptamine) comes from certain types of mushrooms found in tropical and subtropical regions of South America, Mexico, and the United States. Some common names for Blotter sheet of LSD-soaked paper squares that users psilocybin include little smoke, magic put in their mouths. mushrooms, and shrooms. Photo by © DEA • Peyote (mescaline) is a small, spineless cactus with mescaline as its main ingredient. Peyote can also be synthetic.
    [Show full text]
  • Introduction
    Guidance for Assay Development & HTS March 2007 Version 5 Section I: Introduction Introduction Copyright © 2005, Eli Lilly and Company and the National Institutes of Health Chemical Genomics Center. All Rights Reserved. For more information, please review the Privacy Policy and Site Usage and Agreement. Table of Contents A. INTRODUCTION This document is written to provide guidance to investigators that are interested in developing assays useful for the evaluation of compound collections to identify chemical probes that modulate the activity of biological targets. Originally written as a guide for therapeutic projects teams within a major pharmaceutical company, this manual has been adapted to provide guidelines for: a. Identifying potential assay formats compatible with High Throughput Screen (HTS), and Structure Activity Relationship (SAR) b. Developing optimal assay reagents c. Optimizing assay protocol with respect to sensitivity, dynamic range, signal intensity and stability d. Adopting screening assays to automation and scale up in microtiter plate formats e. Statistical validation of the assay performance parameters f. Secondary follow up assays for chemical probe validation and SAR refinement g. Data standards to be followed in reporting screening and SAR assay results. General definition of biological assays This manual is intended to provide guidance in the area of biological assay development, screening and compound evaluation. In this regard an assay is defined by a set of reagents that produce a detectable signal allowing a biological process to be quantified. In general, the quality of an assay is defined by the robustness and reproducibility of this signal in the absence of any test compounds or in the presence of inactive compounds.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • The Use of Psychedelic Drugs in the Treatment of Problematic Drug and Alcohol Use
    Tripping up addiction: The use of psychedelic drugs in the treatment of problematic drug and alcohol use Short Title: Illicit drugs in the treatment of addiction Celia Morgan 1,3, Amy McAndrew1, Tobias Stevens1, David Nutt2, Will Lawn1,3 1. Psychopharmacology and Addiction Research Centre, University of Exeter, UK 2. Centre for Neuropsychopharmacology, Imperial College London, UK 3. Clinical Psychopharmacology Unit, University College London, UK Address Corrrespondence to: Celia Morgan Psychopharmacology and Addiction Research Centre Washington Singer Laboratory University of Exeter Perry Road, Exeter Devon UK EX4 4QG Key words: addiction, psychedelics, ketamine, ibogaine, ayahuasca, LSD , psilocybin, neurogenesis, 1 Highlights: Psilocybin may reduce alcohol and tobacco use in addicted samples. Ibogaine and ayahuasca have shown promise in the treatment of various addictions through observational studies. Ketamine has been used to treat alcohol dependence and reduces cocaine self- administration in the human laboratory. Randomised controlled trials are greatly needed to further test the efficacy of all of these compounds. Psychedelic drugs may have their therapeutic qualities due to anti-depressant effects, stimulating neuroplasticity and long-term psychological changes. 2 Abstract Psychedelic drugs have been used as treatments in indigenous cultures for thousands of years. Yet, due to their legal status, there has been limited scientific research into the therapeutic potential of these compounds for psychiatric disorders. In the absence of other effective treatments however, researchers have begun again to systematically investigate such compounds and there is now evidence pointing to the use of psychedelic drugs in the treatment of addiction. In this review we focus on human evidence for the effectiveness of preparations used by indigenous cultures in the Amazon (ayahausca) and Africa (ibogaine) and worldwide (psilocybin), and more recently synthetised drugs such as the serotonergic hallucinogen LSD and the dissociative anaesthetic ketamine.
    [Show full text]
  • Ketamine Homogeneous Enzyme Immunoassay (HEIA™)
    Ketamine Homogeneous Enzyme Immunoassay (HEIA™) Exclusively from Immunalysis Formula: C13H16CINO Semi-Quantitative or Qualitative Testing Systematic Name: (RS)- 2- (2- chlorophenyl)- 2- (methylamino)cyclohexanone Accurate and reliable Brand Names: Ketanest®, Ketaset®, Ketalar® Ready to use About Ketamine: Ketamine is an anesthetic agent used in the United States since 1972 for veterinary and pediatric medicine. It is also used in the treatment of depression and postoperative pain management. However, in recent years it has gained popularity as a street drug used at clubs and raves due to its hallucinogenic effects. Administration: Oral; intravenous; intramuscular; insufflation Elimination: Ketamine metabolizes by N-demethylation to Norketamine and further dehydrogenates to Dehydronorketamine. After 72 hours of a single dose, 2.3% of Ketamine is unchanged, 1.6% is Norketamine, 16.2% is Dehydronorketamine, and 80% is hydroxylated derivatives of Ketamine.1,2 Abuse Potential: An overdose can cause unconsciousness and dangerously slowed breathing. 1) R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, Fourth Edition, p. 412-414. 2) K. Moore, J.Skerov, B.Levine, and A.Jacobs, Urine Concentrations of Ketamine and Norketamine Following Illegal Consumption, J.Anal, Toxicol. 25: 583-588 (2001). Ketanest® is a registered trademark of Pfizer, Inc., Ketaset® is a trademark of ZOETIS W LLC., Ketalar® is a trademark of PAR STERILE PRODUCTS, LLC. Tel 909.482.0840 | Toll Free 888.664.8378 | Fax 909.482.0850 ISO13485:2003 www.immunalysis.com CERTIFIED
    [Show full text]
  • Ketamine-Assisted Psychotherapy (KPT) of Heroin Addiction: Immediate Effects and Six Months Follow-Up
    Ketamine-Assisted Psychotherapy (KPT) of Heroin Addiction: Immediate Effects and Six Months Follow-Up Evgeny M. Krupitsky, M.D., Ph.D. Andrey M. Burakov, M.D., Ph.D. Tatyana N. Romanov, Ph.D. Alexander Y. Grinenko, M.D., Ph.D. Rick J. Strassman, M.D. In the 20th century, while billions of dollars have these substances had essentially come to an end in been spent to treat addictive diseases, the search for America because of controversy associated with their effective medication continues. The mainstay of such non-medical use (Halpern, 1996). treatments includes therapy and counseling, AA and Later in the 1980's and 1990's both animal studies NA, different kinds of rehabilitation programs, drug and anecdotal human reports suggested anti-craving maintenance programs, and pharmacotherapy. The ef- properties of another hallucinogen--ibogaine ficacy of all these suggested methods of addiction treat- ("Endabuse") (Lotsof, 1995; Mash, 1998). However, ment is not enough, however, and still there is a need further human research with ibogaine is needed to dem- for new effective medications. The use of hallucino- onstrate its antiaddictive properties as well as safety. gens in the treatment of addictions could be one prom- Ketamine is a drug for general anesthesia, but in ising approach (Halpern, 1996). subanesthetic doses it induces a profound psychedelic Many addiction studies in the 1950's and 1960's (hallucinogenic) experience (Bowdle et al., 1998). (Grinspoon and Bakalar, 1979), suggested that hallu- Ketamine has several advantages over other halluci- cinogen-assisted (psychedelic) psychotherapy might be nogens as an adjunct to psychotherapy in the treat- an efficient treatment, but different methodologies ment of addictions: it is safe, short-acting, and, most made it difficult to generalize across studies.
    [Show full text]
  • DXM Fast Facts
    What is DXM? doses—usually at least half an 8-ounce ketamine. While under the influence of bottle—by drinking the liquid very the drug, which can last for as long as DXM (dextromethorphan) is a quickly. (Consumption of large quanti- 6 hours, DXM abusers risk injuring cough suppressant available in a ties of cough syrup induces vomiting. themselves and others because of the variety of over-the-counter cough and Thus, to achieve the desired effects, drug’s effects on visual perception and cold medications. DXM is abused abusers must drink the product quickly cognitive processes. because, when taken in doses that enough to allow the body to absorb the In addition, individuals who ingest dramatically exceed those recom- DXM before vomiting occurs.) mended by physicians and pharma- high doses of DXM risk hyperthermia cists, it produces hallucinations and The availability of powdered extrac- (exceptionally high fever), particularly if a sense of dissociation. tions of DXM has resulted in abusers they use the drug in a hot environment either inhaling the powder (snorting) or or while physically exerting themselves— What does DXM look like? repackaging it in capsules, which are such as at a rave or dance club. Other then swallowed. risks associated with DXM abuse As an over-the-counter medication, include nausea, abdominal pain, vomit- DXM is available in various forms Who abuses DXM? ing, irregular heartbeat, high blood including liquids, lozenges, tablets, pressure, headache, numbness of capsules, and gel caps. In addition, DXM It is difficult to gauge the extent of fingers and toes, loss of consciousness, powder—prepared by extracting the drug DXM abuse in the United States seizures, brain damage, and death.
    [Show full text]